MX2014001920A - Proteina de fusion acortada de tetranectina-apolipoproteina a-i, una particula lipidica que la contiene, y usos de la misma. - Google Patents
Proteina de fusion acortada de tetranectina-apolipoproteina a-i, una particula lipidica que la contiene, y usos de la misma.Info
- Publication number
- MX2014001920A MX2014001920A MX2014001920A MX2014001920A MX2014001920A MX 2014001920 A MX2014001920 A MX 2014001920A MX 2014001920 A MX2014001920 A MX 2014001920A MX 2014001920 A MX2014001920 A MX 2014001920A MX 2014001920 A MX2014001920 A MX 2014001920A
- Authority
- MX
- Mexico
- Prior art keywords
- apolipoprotein
- fusion protein
- lipid particle
- particle containing
- shortened tetranectin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/7056—Lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
Abstract
Aquí se describe una proteína de fusión tetranectina-apolipoproteí na A-I acortada y una partícula lipídica que comprende la proteína de fusión tetranectina-apolipoproteína A-I acortada así como la utilización de las mismas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11178746 | 2011-08-25 | ||
PCT/EP2012/066301 WO2013026860A1 (en) | 2011-08-25 | 2012-08-22 | Shortened tetranectin-apolipoprotein a-i fusion protein, a lipid particle containing it, and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2014001920A true MX2014001920A (es) | 2014-04-14 |
Family
ID=46704687
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014001920A MX2014001920A (es) | 2011-08-25 | 2012-08-22 | Proteina de fusion acortada de tetranectina-apolipoproteina a-i, una particula lipidica que la contiene, y usos de la misma. |
Country Status (11)
Country | Link |
---|---|
US (2) | US8791063B2 (es) |
EP (1) | EP2748191A1 (es) |
JP (2) | JP6207507B2 (es) |
KR (1) | KR20140054115A (es) |
CN (1) | CN103703023A (es) |
AR (1) | AR087640A1 (es) |
BR (1) | BR112013033562A2 (es) |
CA (1) | CA2838070A1 (es) |
MX (1) | MX2014001920A (es) |
RU (1) | RU2014108240A (es) |
WO (1) | WO2013026860A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018223118A1 (en) * | 2017-06-02 | 2018-12-06 | The Feinstein Institute For Medical Research | Use of tetranectin and peptide agonists to treat inflammatory diseases |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4608347A (en) | 1982-04-15 | 1986-08-26 | Bernstam Victor A | Compositions, uses and methods creating reverse micelles for the clarification of biological fluids to obtain undistorted assay of analytes following clarification |
CH683101A5 (de) | 1990-09-18 | 1994-01-14 | Biotech Australia Pty Ltd | T-Zellen-Epitope. |
SE9103701D0 (sv) | 1991-12-13 | 1991-12-13 | Kabi Pharmacia Ab | Apolipoprotein |
ATE282092T1 (de) | 1997-06-11 | 2004-11-15 | Borean Pharma As | Trimerisierendes modul |
US6518412B1 (en) | 1997-09-29 | 2003-02-11 | Jean-Louis Dasseux | Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
US6291245B1 (en) | 1998-07-15 | 2001-09-18 | Roche Diagnostics Gmbh | Host-vector system |
EP0972838B1 (en) | 1998-07-15 | 2004-09-15 | Roche Diagnostics GmbH | Escherichia coli host/vector system based on antibiotic-free selection by complementation of an auxotrophy |
AU2001253620A1 (en) | 2000-04-14 | 2001-10-30 | Nuvelo, Inc. | Materials and methods relating to lipid metabolism |
JP4344136B2 (ja) * | 2000-11-10 | 2009-10-14 | エフ・ホフマン−ラ・ロシュ・リミテッド | アポリポタンパク質類似体 |
ITMI20021058A1 (it) | 2002-05-17 | 2003-11-17 | Chiesi Farma Spa | Miscele di lipidi sintetici ottimizzate per la preparazione di un surfattante ricostituito |
EP1511508A4 (en) * | 2002-05-17 | 2009-07-08 | Esperion Therapeutics Inc | METHOD FOR TREATING DYSLIPIDARY INTERFERENCE |
EP1556413A4 (en) | 2002-05-17 | 2009-07-08 | Esperion Therapeutics Inc | METHODS AND COMPOSITIONS FOR TREATING ISCHEMIC REPERFUSION |
AU2003239777A1 (en) * | 2002-07-05 | 2004-01-23 | Borean Pharma A/S | Multimerised growth hormone fusion proteins |
CA2443365C (en) | 2002-11-19 | 2010-01-12 | F. Hoffmann-La Roche Ag | Methods for the recombinant production of antifusogenic peptides |
US20040180445A1 (en) | 2003-03-12 | 2004-09-16 | Domanico Michael J. | Methods and compositions for purification of nucleic acid from a host cell |
EP1486571B1 (en) | 2003-06-12 | 2005-12-14 | F. Hoffmann-La Roche Ag | Method for the recombinant production of polypeptides |
PE20050438A1 (es) | 2003-10-20 | 2005-06-14 | Esperion Therapeutics Inc | Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos |
WO2005041886A2 (en) | 2003-10-31 | 2005-05-12 | Metaphore Pharmaceuticals, Inc. | Methods for generating or increasing revenues related to pain inhibitor commerce |
CA2551896A1 (en) | 2003-12-30 | 2005-07-21 | Wyeth | Formulations of hydrophobic proteins in an immunogenic composition having improved tolerability |
WO2005084642A1 (en) | 2004-01-28 | 2005-09-15 | Biodelivery Sciences International, Inc. | Apoprotein cochleate compositions |
US20090143276A1 (en) * | 2007-10-08 | 2009-06-04 | Anaphore, Inc. | Trimeric IL-1Ra |
US20100028995A1 (en) | 2004-02-23 | 2010-02-04 | Anaphore, Inc. | Tetranectin Trimerizing Polypeptides |
KR100560102B1 (ko) | 2004-06-25 | 2006-03-13 | 한국생명공학연구원 | 프로아포리포단백질 a-ⅰ 변이체와, 이를 포함하는고지혈증 또는 동맥경화증 예방 및 치료제 |
US20060110788A1 (en) | 2004-10-01 | 2006-05-25 | Invitrogen Corporation | Feeding buffers, systems, and methods for in vitro synthesis of biomolecules |
WO2006047614A2 (en) | 2004-10-26 | 2006-05-04 | Invitrogen Corporation | Compositions and methods for analyzing biomolecules using mass spectroscopy |
WO2006069371A1 (en) | 2004-12-22 | 2006-06-29 | Baylor College Of Medicine | A method of plasma lipidation to prevent, inhibit and/or reverse atherosclerosis |
US8206750B2 (en) | 2005-03-24 | 2012-06-26 | Cerenis Therapeutics Holding S.A. | Charged lipoprotein complexes and their uses |
EP1896074A4 (en) | 2005-05-25 | 2009-04-22 | Liponex Inc | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF CORONARY ARTERY DISEASE |
US20080248565A1 (en) | 2007-03-01 | 2008-10-09 | Invitrogen Corporation | Isolated phospholipid-protein particles |
US20070254832A1 (en) | 2006-02-17 | 2007-11-01 | Pressler Milton L | Methods for the treatment of macular degeneration and related eye conditions |
MX2008015337A (es) | 2006-06-01 | 2009-11-26 | Inst Cardiologie Montreal | Metodo y compuesto para el tratamiento de estenosis valvular. |
EP2069487B1 (en) | 2006-07-25 | 2014-03-19 | Agilent Technologies, Inc. | Zwitterionic detergents for the storage and use of dna polymerases |
WO2008017906A1 (en) | 2006-08-10 | 2008-02-14 | Plantechno S.R.L. | In-plant production of dimeric and/or oligomeric (comprising three or more units) forms of human apo a-1 protein muteins |
WO2008094905A2 (en) | 2007-01-29 | 2008-08-07 | Lipid Sciences, Inc. | Encapsulated hdl mimetic peptides |
FR2915490B1 (fr) | 2007-04-26 | 2011-10-28 | Univ Joseph Fourier Grenoble I | Formation de proteoliposomes contenant des proteines membranaires a l'aide d'un systeme de synthese proteique acellulaire |
WO2008156873A2 (en) | 2007-06-20 | 2008-12-24 | Merck & Co., Inc. | Apoa-1 peptide mimetics |
WO2009036460A2 (en) | 2007-09-14 | 2009-03-19 | Ambrx, Inc. | Modified human apolipoprotein a-i polypeptides and their uses |
JP2010539995A (ja) * | 2007-10-08 | 2010-12-24 | アナフォア インコーポレイテッド | 三量体IL−1Ra |
US8999320B2 (en) | 2008-01-30 | 2015-04-07 | The Rockefeller University | Nanoscale bound bilayers, methods of use and production |
DK2288336T3 (en) | 2008-04-25 | 2017-03-13 | Univ Northwestern | NANOSTRUCTURES SUITABLE FOR COMPLEXATION OF CHOLESTEROL |
CN102123737B (zh) * | 2008-06-13 | 2014-01-01 | 西马生物医学计划公司 | 用于生物活性化合物施用的轭合物 |
EP2389189A4 (en) | 2009-01-23 | 2012-12-19 | Inst Cardiologie Montreal | METHOD FOR PREVENTING AND TREATING DIASTOLIC DYSFUNCTION USING APOLIPOPROTEIN-A1 MIMETIC PEPTIDE / PHOSPHOLIPID COMPLEX (APOA1) |
US20110086770A1 (en) * | 2009-10-09 | 2011-04-14 | Anaphore, Inc. | Combinatorial Libraries Based on C-type Lectin-like Domain |
KR101584414B1 (ko) | 2010-08-30 | 2016-01-13 | 에프. 호프만-라 로슈 아게 | 알칼리 공급원 |
RU2013111677A (ru) | 2010-08-30 | 2014-10-10 | Ф. Хоффманн-Ля Рош Аг | Конструкция для экспрессии у прокариот |
US20120190609A1 (en) | 2010-08-30 | 2012-07-26 | Martin Bader | Method for producing a lipid particle, the lipid particle itself and its use |
AR082644A1 (es) | 2010-08-30 | 2012-12-19 | Hoffmann La Roche | Tetranectina-apolipoproteina a-i, particulas lipidicas que la contiene y utilizacion de la misma relacionado con el metabolismo de los lipidos y las enfermedades cardiovasculares |
JP6116565B2 (ja) | 2011-08-25 | 2017-04-19 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 陽イオンおよび陰イオン交換クロマトグラフィー法 |
CN104144939A (zh) | 2012-02-29 | 2014-11-12 | 霍夫曼-拉罗奇有限公司 | 柱上酶切割 |
KR20150009953A (ko) | 2012-02-29 | 2015-01-27 | 에프. 호프만-라 로슈 아게 | 1→3 해독 프레임 이동의 감소 방법 |
EP2820040A1 (en) | 2012-02-29 | 2015-01-07 | F. Hoffmann-La Roche AG | Method for reduction of 1->2 reading frame shifts |
-
2012
- 2012-08-22 RU RU2014108240/10A patent/RU2014108240A/ru not_active Application Discontinuation
- 2012-08-22 WO PCT/EP2012/066301 patent/WO2013026860A1/en active Application Filing
- 2012-08-22 US US13/592,183 patent/US8791063B2/en not_active Expired - Fee Related
- 2012-08-22 BR BR112013033562A patent/BR112013033562A2/pt not_active IP Right Cessation
- 2012-08-22 CA CA2838070A patent/CA2838070A1/en not_active Abandoned
- 2012-08-22 MX MX2014001920A patent/MX2014001920A/es unknown
- 2012-08-22 KR KR1020147004659A patent/KR20140054115A/ko not_active Application Discontinuation
- 2012-08-22 EP EP12748504.3A patent/EP2748191A1/en not_active Withdrawn
- 2012-08-22 CN CN201280036904.9A patent/CN103703023A/zh active Pending
- 2012-08-22 JP JP2014526485A patent/JP6207507B2/ja not_active Expired - Fee Related
- 2012-08-23 AR ARP120103098A patent/AR087640A1/es not_active Application Discontinuation
-
2014
- 2014-06-25 US US14/315,187 patent/US9139640B2/en not_active Expired - Fee Related
-
2017
- 2017-04-27 JP JP2017088198A patent/JP2017171670A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2013026860A1 (en) | 2013-02-28 |
US8791063B2 (en) | 2014-07-29 |
RU2014108240A (ru) | 2015-09-27 |
US20150011459A1 (en) | 2015-01-08 |
KR20140054115A (ko) | 2014-05-08 |
US20130231273A1 (en) | 2013-09-05 |
CA2838070A1 (en) | 2013-02-28 |
CN103703023A (zh) | 2014-04-02 |
AR087640A1 (es) | 2014-04-09 |
JP2017171670A (ja) | 2017-09-28 |
BR112013033562A2 (pt) | 2017-02-14 |
EP2748191A1 (en) | 2014-07-02 |
JP6207507B2 (ja) | 2017-10-04 |
JP2014529602A (ja) | 2014-11-13 |
US9139640B2 (en) | 2015-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP4223770A3 (en) | Novel fusion molecules and uses thereof | |
MX2019003214A (es) | Formulaciones de proteina de inmunoglobulina del dominio variable dual estable. | |
EP2807799B8 (en) | Fallback messaging | |
CA144407S (en) | Lighting | |
EP2709603A4 (en) | MODIFIED BIOTIN-BINDING PROTEIN, FUSION PROTEINS AND APPLICATIONS THEREWITH | |
WO2012139134A3 (en) | Methods of modulating oncogenic fusion proteins | |
MY168166A (en) | Polymer and Composition Including Same, and Adhesive Composition | |
MX368288B (es) | Una combinación de anticuerpos anti-cd38 y melfalán para usarse en el tratamiento de mieloma múltiple. | |
CA147873S (en) | Teapot | |
EP2698386B8 (en) | Fusion protein | |
CA145279S (en) | Loudspeaker | |
WO2012078816A9 (en) | Proteins that efficiently generate singlet oxygen | |
MY157836A (en) | Laminate | |
CA141191S (en) | Packaging | |
EP2521143B8 (de) | Magnetisch wirksamer Werkstoff | |
IN2012DE02272A (es) | ||
MX2014001920A (es) | Proteina de fusion acortada de tetranectina-apolipoproteina a-i, una particula lipidica que la contiene, y usos de la misma. | |
WO2013095994A3 (en) | Transparent aqueous fragrance microemulsions | |
CA141192S (en) | Packaging | |
CA141190S (en) | Packaging | |
CA145236S (en) | Pitcher | |
AU2012101533A4 (en) | The Wheelie Fast | |
AU338253S (en) | Retail Unloader | |
AU2011904403A0 (en) | The Ducks foot | |
CA145280S (en) | Loudspeaker |